News headlines about Endocyte (NASDAQ:ECYT) have trended positive on Friday, according to AlphaOne. AlphaOne, a division of Accern, scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endocyte earned a coverage optimism score of 0.31 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biopharmaceutical company an impact score of 85 out of 100, indicating that recent media coverage is very likely to have an impact on the company’s share price in the near future.
Several equities analysts have recently issued reports on ECYT shares. Zacks Investment Research lowered shares of Endocyte from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 17th. Cowen and Company restated a “buy” rating on shares of Endocyte in a report on Wednesday, April 5th.
Shares of Endocyte (NASDAQ:ECYT) traded down 1.35% during trading on Friday, reaching $2.20. 435,090 shares of the company were exchanged. The company’s 50-day moving average is $2.35 and its 200 day moving average is $2.57. The firm’s market capitalization is $93.43 million. Endocyte has a 1-year low of $1.98 and a 1-year high of $4.19.
Endocyte (NASDAQ:ECYT) last issued its earnings results on Friday, March 10th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.01. Endocyte had a negative return on equity of 25.17% and a negative net margin of 57,108.57%. The business had revenue of $0.01 million for the quarter. During the same period in the previous year, the business posted ($0.23) earnings per share. Endocyte’s revenue was up .0% compared to the same quarter last year. Equities research analysts expect that Endocyte will post ($1.17) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.themarketsdaily.com/2017/04/21/positive-media-coverage-very-likely-to-impact-endocyte-ecyt-share-price.html.
Endocyte Company Profile
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.